

Interim report 1 January – 30 June 2022

A quarter in change

1 APRIL – 30 JUNE 2022 (3 MONTHS)


- Net sales decreased by 9 percent to SEK 2,079m (2,276), of which acquired growth amounted to 13 percent. The COVID-19 related net sales decreased by 88 percent. The organic growth, excluding net sales related to COVID-19, was 4 percent.
- EBITA decreased by 28 percent to SEK 240m (332), corresponding to an EBITA-margin of 11.6 percent (14.6).
- Profit after tax decreased by 57 percent to SEK 76m (178).
- Earnings per share amounted to SEK 0.63 (1.47).
- Cash flow from operating activities amounted to SEK 206m (200).
- During the quarter, two acquisitions, BioCat GmbH and O'Flynn Medical Ltd, were completed and after the end of the quarter, one more acquisition, JK Lab Nordic AB, were completed. In total, these acquisitions are estimated to contribute with annual net sales of approximately SEK 180m and approximately 60 employees.

1 JANUARY – 30 JUNE 2022 (6 MONTHS)

- Net sales increased by 16 percent to SEK 4,658m (4,012), of which acquired growth amounted to 30 percent. The COVID-19 related net sales decreased by 59 percent. The organic growth, excluding net sales related to COVID-19, was 3 percent.
- EBITA increased by 3 percent to SEK 675m (658), corresponding to an EBITA-margin of 14.5 percent (16.4).
- Profit after tax decreased by 26 percent to SEK 301m (404).
- Earnings per share amounted to SEK 2.47 (3.46). Earnings per share for the last 12 months amounted to SEK 5.07 (6.03).
- Cash flow from operating activities amounted to SEK 538m (384).
- The equity ratio was 36 percent (40).
- Return on working capital (P/WC) amounted to 74 percent (95).
- During the interim period, four acquisitions were made and another after the end of the interim period. The acquisitions are expected to contribute with annual net sales of approximately SEK 855m.
- AddLife's new President and CEO Fredrik Dalborg will start on September 1st.


SEKm	3 months ending			6 months ending			12 months ending	
	30 Jun 22	30 Jun 21	change	30 Jun 22	30 Jun 21	change	30 Jun 22	31 Dec 21
Net sales	2,079	2,276	-9%	4,658	4,012	16%	8,639	7,993
EBITA	240	332	-28%	675	658	3%	1,290	1,273
EBITA-margin, %	11.6%	14.6%		14.5%	16.4%		14.9%	15.9%
Profit before tax	94	237	-60%	383	524	-27%	786	927
Profit for the period	76	178	-57%	301	404	-26%	618	721
Earnings per share before dilution, SEK	0.63	1.47	-57%	2.47	3.46	-29%	5.07	6.03
Earnings per share after dilution, SEK	0.62	1.46	-58%	2.46	3.44	-28%	5.04	6.01

NET SALES (SEKM)



■ Quarter
— Rolling 12 months

EBITA (SEKM)



■ Quarter
— Rolling 12 months

ADDLIFE IN BRIEF

AddLife is an independent provider in Life Science that offers high-quality products, services and advice to both the private and public sector in Europe. The Group is divided into two business areas: Labtech and Medtech. The Group comprises some 85 operating subsidiaries that provide equipment, instruments, medical devices and reagents, as well as advice and technical support to customers primarily in healthcare, research and academia, along with the food and pharmaceutical industries.

CONFERENCE CALL

Investors, analysts and the media are invited to a conference call where CEO Kristina Willgård and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10:00 a.m. on July 15th, 2022

If you wish to participate via teleconference, [please follow this link](#)>>

Or call in (only sound) +46 8 505 376 58 Conferens-ID: 915 124 356#

The presentation is also available on [AddLife YouTube](#) >>

Comments by the CEO

Market conditions in the second quarter have been changing! Just as expected, sales of COVID-19-related products have declined sharply compared to the corresponding quarter last year, when it was on record level. Growth is instead attributable to the acquisitions in Europe in recent years, as well as to the segments that reported weaker growth during the pandemic. Sales in the quarter decreased by 9 percent to SEK 2,079 million, due to the sharp decrease by 88 percent of COVID-19 related products. The organic growth excluding COVID-19 related sales amounted to 4 percent. The big changes in the quarter have led to decreased result and EBITA margin compared to last year. Accumulated for the interim period the net sales increased with 16 percent to SEK 4,658m, EBITA increased by 3 percent to SEK 675m and the EBITA margin amounted to 14.5 percent.

The world is turbulent due to the war in Ukraine, and the global economy has been hit by rising inflation and higher interest rates. It is still difficult to assess how this will impact our different market segments. However, we are confident that we are operating in a relatively stable market with underlying demographically driven demand, and we are working systematically to ensure long-term margins and profitability. We know from experience that our decentralised business model based on agile entrepreneurial companies is a strength, when market conditions are changing.

During the quarter, markets have become increasingly normalised and activity is almost in full swing. Our companies have been able to meet both customers and suppliers, promoted new products and solutions and expanded their presence at various trade fairs. In addition, Health services has also increased the number of planned operations and other treatments in most markets. However, a general shortage of healthcare workers and a recurrent spread of infection via new mutations are limiting the pace of recovery.

Challenges remain in global supply chains, in the form of raw material and component shortages, increased costs and long lead times. Against that background, some of our companies have increased stocks in the short term in order to continue to provide customers with a high level of service. During the interim period, our subsidiaries have been able to absorb the higher costs and secure their margins by compensating through price adjustments in both existing and new customer contracts, as well as through efficiency improvements.



It is with confidence we look forward to continue to develop our platform to meet rising demand driven by a growing and ageing population.

Sales in the Labtech business area decreased in the quarter due to significantly lower volumes of PCR tests as well as COVID-19-related products to research customers. Market activity is high in our companies in both diagnostics and research, and underlying sales of both reagents and instruments have increased in the quarter.

Sales in the Medtech business area increased, with growth driven by a return to more normal conditions and activities in hospitals. Both elective surgery and other medical device products has had robust sales growth. Demand has also increased at all home care companies in the quarter. There is a great interest in our new digital solutions for self-monitoring and we continuously invest in the further development of the digital platform. Development costs of SEK 11m were charged to profit in the quarter.

A year of integration, consolidation and selective acquisitions

The strong European platform that AddLife has created through several acquisitions in recent years has underpinned our ability to excel our goal of 15 percent EBITA growth. We are working in a focused way on integrating our acquisitions and ensuring that our new employees get to know our vision and corporate philosophy through AddLife Academy. We are also building networks between our companies so that we can share all of our expertise. 2022 is a year of integration and consolidation of our Group and we also intend to reduce our net debt. We continue to actively engage in dialogue with interesting companies for future acquisitions.

On 1 April, we acquired the companies O'Flynn Medical and BioCat, who together has net sales of approximately SEK 155m and 42 employees. After the end of the quarter, the Swedish company JK Lab was acquired, who has sales of approximately SEK 25 million and 6 employees. So far this year, we have completed five acquisitions with annual sales of approximately SEK 855m.

In summary, it has been a quarter of transition. By reinvesting part of our COVID-19-related profits, we have been able to build a strong European market presence in selected niches. It is with confidence we look forward to continue to develop our platform to meet rising demand driven by a growing and ageing population.

A big thank you

This is my last report as President and CEO of AddLife and I would like to thank all of you who I have had the privilege to work with. I am immensely proud of how AddLife has developed, with our decentralised business model, strong corporate culture and shared values. Together, we have been on a fantastic journey and laid the foundation for continued long-term sustainable and profitable growth. It is now with great confidence that, on September 1st, I will hand over to our new President and CEO, Fredrik Dalborg. I am confident that Fredrik, along with our dedicated and experienced employees, will continue to drive and develop AddLife into an even bigger and better company with care for employees, customers and partners.




Kristina Willgård

President and CEO

Group development in the quarter

Net sales in the quarter decreased by 9 percent to SEK 2,079m (2,276). The acquired growth totalled 13 percent and organic growth, excluding COVID-19 amounted to 4 percent. Net sales related to COVID-19 decreased significantly to SEK 87m (704). Exchange rate changes had a positive impact of 2 percent on net sales in the quarter, corresponding to SEK 57m.

NET SALES 3 MONTHS




EBITA decreased by 28 percent to SEK 240m (332) and EBITA-margin amounted to 11.6 percent (14.6). Development cost regarding digital solutions for self-monitoring has had a negative impact on the result of SEK 11m in the Medtech business area. Exchange rate changes had a positive effect on EBITA, corresponding to SEK 6m.

Net financial items amounted to SEK -44m (-16) and profit after financial items amounted to SEK 94m (237). The increased negative net financial items is due to interest costs related to the acquisitions and exchange rate fluctuations. Interest expenses amounted to SEK 22m and exchange rate losses to SEK 27m. Exchange rate losses are related to recalculation of loans and contingent considerations in foreign currencies. Profit after tax for the quarter decreased by 57 percent to SEK 76m (178) and the effective tax rate was 19 percent (25). The decreased effective tax rate is due to non-deductible transaction related costs in the quarter last year.

Group development in the interim period


Net sales in the interim period increased by 16 percent to SEK 4,658m (4,012). Acquired growth totalled 30 percent and organic growth, excluding COVID-19 amounted to 3 percent. Net sales related to COVID-19 decreased significantly to SEK 546m (1,323). Exchange rate changes had a positive impact on net sales of 3 percent, corresponding to SEK 148m.

NET SALES 6 MONTHS



EBITA increased by 3 percent to SEK 675m (658) and EBITA-margin amounted to 14.5 percent (16.4). Development cost regarding digital solutions for self-monitoring has had a negative impact on the result of SEK 14m in the Medtech business area. Exchange rate changes had a positive effect on EBITA, corresponding to SEK 21m.


COVID-19 RELATED SALES



Throughout the COVID-19 pandemic, AddLife has supplied large volumes of products to the healthcare sector for treatment of COVID-19. Sales since the first quarter of 2020 have varied based on the spread of infection and restrictions in our societies.

Net financial items amounted to SEK -93m (-20) and profit after financial items amounted to SEK 383m (524). The increased negative net financial items is due to interest costs related to the acquisitions as well as exchange rate losses. Interest expenses amounted to SEK 43m and exchange rate losses to SEK 52m. Exchange rate losses are related to recalculation of loans and contingent considerations in foreign currencies. Profit after tax decreased with 26 percent amounting to SEK 301m (404) and the effective tax rate was 21 percent (23).

NET SALES PER MARKET 2022



Sales in the Nordic markets amounted to 35 percent of total net sales compared to 49 percent last year (full year 2021). The change in geographical markets is due to the acquisitions in Europe during 2021-2022.

The war in Ukraine has not had a significant economic impact on the financial reports, but it can not be ruled out that this will happen in the future. We follow market developments closely, where we notice rising inflation, higher raw material and shipping costs and greater uncertainty about interest rate developments.

Financial position and cash flow

At the end of the interim period, the equity ratio stood at 36 percent (40). Equity per share totalled SEK 37.30 (35.14) and the return on equity at the end of the quarter was 14 percent (22). Return on working capital, P/WC (EBITA in relation to working capital) amounted to 74 percent (95). The slight decrease is mainly due to a relatively higher working capital, due to acquisitions.


The Group's interest-bearing net debt at the end of the interim period totalled SEK 5,557m (3,870), including pension liabilities of SEK 67m (82) and leasing liabilities of SEK 365m (339). The net debt/equity ratio, calculated on the basis of net debt including provisions for pensions and leasing liability, totalled 1.2 compared to 0.9 at the beginning of the interim period. The acquisitions made during the last few years have been financed through increased debt. In connection with the accession of MBA Incorporado S.L, new loans of EUR 98.5m were taken out, whereof EUR 39.5m were used for debt settlement. The credit agreement runs for 12 months with an extension option of up to a further 24 months. The group has good margin in the covenants according to the bank agreements and we intend to lower net debt through own cash flow.

Cash and cash equivalents, consisting of cash and bank balances, together with approved but non-utilised credit facilities, totalled SEK 448m (674) on June 30, 2022.


Cash flow from operating activities reached SEK 538m (384) during the interim period. The change is mainly due to improved working capital compared with previous year. Acquisitions of companies amounted to SEK 796m (2,514). Net investments in non-current assets during the interim period amounted to SEK 128m (64). The increase is attributable to investments in instruments for rental to customers. Repurchase of treasury shares amounted to SEK 49m (0). Exercised, issued and repurchased call options amounted to SEK 5m (-5). Dividend paid to the parent company's shareholders amounted to SEK 243m (183).

Long term financial goals

PROFITABILITY P/WC (%)



PROFIT GROWTH (%)



Acquisitions

Acquisitions completed from the 2021 financial year are distributed among the Group's business areas as follows:

Acquisitions	Time	Net Sales, SEKm*	Number of employees*	Business area
AddVision, Germany	April, 2021	700	190	Medtech
Healthcare 21 Group, Ireland	April, 2021	1,700	450	Medtech
Bio-Connect Group, Netherlands	September, 2021	140	31	Labtech
Fischer Medical ApS, Denmark	November, 2021	60	12	Medtech
Camanio AB, Sweden	December, 2021	13	18	Medtech
MBA Incorporado S.L, Spain	January, 2022	670	285	Medtech
Business from Telia Health Monitoring, Sweden	March, 2022	4	8	Medtech
O'Flynn Medical Ltd, Ireland	April, 2022	64	36	Medtech
BioCat GmbH, Germany	April, 2022	90	20	Labtech
JK Lab Nordic AB, Sweden	July, 2022	24	6	Labtech
		3,465	1,056	

* Refers to conditions at the time of acquisition on a full-year basis.

Four acquisitions were completed during the interim period:

On December 20, 2021, an agreement was signed to acquire the operations from Telia Health Monitoring to the Medtech business area. Telia Health Monitoring develop and provides a digital platform solution that enables self-monitoring by patients with chronic diseases. Access took place on March 1, 2022 and the business, with sales of SEK 4m, and its eight employees, have been integrated into Camanio.

On December 22, 2021, an agreement was signed to acquire all the shares in MBA Incorporate S.L, a leading Spanish orthopaedic and trauma surgery business. MBA is acquired from Atlanta Private Equity, which owns approximately 75 percent, and a number of minority shareholders, which own 25 percent. The final purchase price amounts to a total of EUR 59 million after debt settlement and is financed through extended credit facilities. MBA will operate as a separate subgroup and will be part of the Medtech business area. The acquisition was completed and the shares accessed on January 20, 2022. MBA has annual net sales of approximately SEK 670m and 285 employees.

On 1 April 2022, AddLife acquired all shares in the Irish company O'Flynn Medical Ltd. O'Flynn Medical is an independent distributor offering product sales, rental and technical services to the hospital sector, private customers and nursing homes in Ireland. The company will become part of the Healthcare 21 Group, which AddLife acquired to the business area Medtech in 2021. O'Flynn has sales of approximately EUR 6.4 million and 36 employees.

On 1 April 2022, AddLife acquired all shares in the German company BioCat GmbH to the Labtech business area. BioCat is a specialized distributor of products and services to the life science research market with annual revenues of EUR 9 million and has 20 employees. The company is located in Germany but also has sales in Austria and Switzerland.

The effect of the acquired companies completed during the interim period on the AddLife Group's net sales was SEK 438m, on EBITA SEK 86m, on operating profit SEK 63m and on profit after tax for the interim period SEK 41m. Had the acquisitions, been completed on January 1, 2022, their impact would have been approximately SEK 479m on net sales, on EBITA SEK 94m and on operating profit SEK 69m and SEK 46m on profit after tax.

According to the preliminary acquisition analyses, the assets and liabilities included in the acquisitions carried out during the financial year 2022 were as follows:

Fair value	Total
Intangible non-current assets	560
Other non-current assets	443
Inventories	271
Other current assets	445
Deferred tax liability/tax asset	-128
Other liabilities	-985
Acquired net assets	606
Goodwill	354
Consideration ¹	960
Less: cash and cash equivalents in acquired businesses	-194
Contingent consideration not yet paid	-16
Effect on the Group's cash and cash equivalents	750

¹ The consideration is stated excluding acquisition expenses.

The goodwill resulting from the acquisitions is attributable to expectations that the Group's position in the market in question for each acquisition will grow stronger and to the knowledge accumulated in the companies acquired. Transaction costs for the acquisitions totalled SEK 12m and are recognised as selling expenses. Revaluation of liabilities for contingent consideration added costs of SEK 4m during the interim period, which is recognised as other operating costs. An additional contingent consideration of SEK 31m has been paid during the interim period regarding the acquisition of Euroclone and Ropox during year 2020.

Employees

At the end of the interim period, the number of employees was 2,194, compared to 1,802 at the beginning of the financial year. During the interim period, the completed acquisitions have led to an increase of 349 employees. The average number of employees for the last 12-month period was 1,943 (1,191).

Labtech


Companies in the Labtech business are active in the market areas diagnostics, biomedical research and laboratory equipment.



MSEK	3 months ending			6 months ending			12 months ending	
	30 Jun 22	30 Jun 21	change	30 Jun 22	30 Jun 21	change	30 Jun 22	31 Dec 21
Net sales	786	1,169	-33%	2,066	2,394	-14%	4,045	4,373
EBITA	117	280	-58%	413	556	-26%	834	977
EBITA-margin, %	14.9%	23.9%		20.0%	23.2%		20.6%	22.3%


Labtech's net sales decreased by 33 percent in the quarter to SEK 786m (1,169), where of organic sales, excluding COVID-19 related sales, amounted to 4 percent and acquired growth was 5 percent. Net sales related to COVID-19 decreased by 85 percent and accounted for SEK 87m (569). Exchange rate changes had positive impact of 2 percent on net sales. EBITA decreased by 58 percent to SEK 117m (280), corresponding to an EBITA-margin of 14.9 percent (23.9).

NET SALES 3 MONTHS



Labtech's net sales decreased by 14 percent in the interim period to SEK 2,066m (2,394), where of organic sales, excluding COVID-19 related sales, amounted to 6 percent and acquired growth was 4 percent. Net sales related to COVID-19 decreased by 51 percent and accounted for SEK 546m (1,108). Exchange rate changes had positive impact of 3 percent on net sales. EBITA decreased by 26 percent to SEK 413m (556), corresponding to an EBITA-margin of 20.0 percent (23.2).


NET SALES 6 MONTHS




For the Labtech business, the changes in the second quarter have been significant due to the decrease in sales of COVID-19 products, compared to last year, and a return to a more normal customer offering. PCR testing has declined in all countries and is now focused on patients requiring hospital care, and hospital staff. Future sales of COVID-19 tests in our diagnostics companies depend entirely on how the pandemic evolves, new mutations and different testing requirements in society. We expect that customers will primarily request combination tests – “4-plex solutions” – for the autumn and winter flu season. Our diagnostics businesses report solid underlying growth in our traditional areas, including blood gas analysis, pathology and microbiology, with increased sample volumes in existing instruments.

Sales to research customers have also been affected by a decrease in sequencing of COVID-19 mutations in the quarter. On the other hand, demand has increased for more traditional laboratory reagents for gene sequencing, cell therapy and cancer immunology. Sales have also increased for instruments and special microscopes, but at the same time delivery times have become extended due to component shortages. In the first half -year, we have seen strong growth in sales of our own advanced instruments in the US, Europe and China.

NET SALES (SEKM)



EBITA (SEKM)



■ Quarter
— Rolling 12 months

■ Quarter
— Rolling 12 months

Medtech


Companies in the Medtech business provides medical device products within the medtech market and assistive equipment within home healthcare.



MSEK	3 months ending			6 months ending			12 months ending	
	30 Jun 22	30 Jun 21	change	30 Jun 22	30 Jun 21	change	30 Jun 22	31 Dec 21
Net sales	1,296	1,108	17%	2,597	1,620	60%	4,602	3,625
EBITA	129	57	127%	273	107	156%	476	310
EBITA-margin, %	10.0%	5.1%		10.5%	6.6%		10.4%	8.6%


For the quarter, Medtech's net sales increased by 17 percent to SEK 1,296m (1,108), of which organic growth, excluding COVID-19 related sales, amounted to 5 percent and acquired growth was 22 percent. Net sales related to COVID-19 accounted for SEK 0m (135). Exchange rate fluctuations had a positive impact of 4 percent on net sales. EBITA increased by 127 percent to SEK 129m (57) and EBITA margin amounted to 10.0 percent (5.1). Development cost regarding digital solutions for self-monitoring has had a negative impact on the result of SEK 11m.

NET SALES 3 MONTHS



For the interim period, Medtech's net sales increased by 60 percent to SEK 2,597m (1,620), of which organic growth, excluding COVID-19 related sales, amounted to 1 percent and acquired growth was 67 percent. Net sales related to COVID-19 accounted for SEK 0m (215). Exchange rate fluctuations had a positive impact of 6 percent on net sales. EBITA increased by 156 percent to SEK 273m (107) and EBITA margin amounted to 10.5 percent (6.6). Development cost regarding digital solutions for self-monitoring has had a negative impact on the result of SEK 14m.

NET SALES 6 MONTHS




The growth in the second quarter in the Medtech business area is driven both by the acquisitions made in recent years as well as by an increase in the number of planned operations. Operations are increasing in all countries, while at the same time the shortage of healthcare workers following the pandemic has restricted capacity. The recurrent spread of new mutations has also led to operations being cancelled at the end of the quarter. In summary, this means that recovery is taking longer and healthcare queues continue to grow.

Sales have increased above all in the orthopaedics, respiratory medicine and endoscopy segments, while ophthalmology and neurology have shown slightly weaker growth. Our largest acquisition from 2021, Healthcare 21, has performed strongly in the quarter while integrating the O'Flynn acquisition in Ireland at the same time. At AddVision, sales in Poland and for self-manufactured products have performed positively, but the recovery in other markets is slower. MBA, which we acquired in the first quarter, delivered as expected.

All home care companies have experienced positive growth in the quarter. Market activity has been buoyant, with an increased number of customer visits and product trials. Interest in our digital solutions for both alarms and self-monitoring is high, and two additional installations were made in Swedish municipalities during the quarter. As planned, we continue to invest in the further development of the acquired digital platform.

NET SALES (SEKM)



EBITA (SEKM)



Net sales by business area

Quarterly data, SEKm	2022				2021	
	Q2	Q1	Q4	Q3	Q2	Q1
Labtech	786	1,280	1,089	890	1,169	1,225
Medtech	1,296	1,301	1,043	962	1,108	512
Group items	-3	-2	-1	-2	-1	-1
AddLife Group	2,079	2,579	2,131	1,850	2,276	1,736

EBITA by business area

Quarterly data, SEKm	2022				2021	
	Q2	Q1	Q4	Q3	Q2	Q1
Labtech	117	296	227	194	280	276
Medtech	129	144	108	95	57	50
Parent Company and Group items	-6	-5	-6	-3	-5	0
EBITA	240	435	329	286	332	326
Depreciation intangible assets	-102	-97	-84	-79	-79	-35
Operating profit	138	338	245	207	253	291
Finance income and expenses	-44	-49	-22	-27	-16	-4
Profit after financial items	94	289	223	180	237	287

Net sales by business area

SEKm	3 months ending			6 months ending			12 months ending	
	30 Jun 22	%	30 Jun 21	30 Jun 22	%	30 Jun 21	30 Jun 22	31 Dec 21
Labtech	786	-33	1,169	2,066	-14	2,394	4,045	4,373
Medtech	1,296	17	1,108	2,597	60	1,620	4,602	3,625
Group items	-3		-1	-5		-2	-8	-5
AddLife Group	2,079	-9	2,276	4,658	16	4,012	8,639	7,993

EBITA and EBITA-margin by business area and operating profit for the group

SEKm	3 months ending				6 months ending				12 months ending			
	30 Jun 22	%	30 Jun 21	%	30 Jun 22	%	30 Jun 21	%	30 Jun 22	%	31 Dec 21	%
Labtech	117	14.9	280	23.9	413	20.0	556	23.2	834	20.6	977	22.3
Medtech	129	10.0	57	5.1	273	10.5	107	6.6	476	10.4	310	8.6
Parent Company and Group items	-6		-5		-11		-5		-20		-14	
EBITA	240	11.6	332	14.6	675	14.5	658	16.4	1,290	14.9	1,273	15.9
Depreciation intangible assets	-102		-79		-199		-114		-362		-277	
Operating profit	138	6.7	253	11.1	476	10.2	544	13.6	928	10.7	996	12.5
Finance income and expenses	-44		-16		-93		-20		-142		-69	
Profit after financial items	94		237		383		524		786		927	

Net sales by revenue type

SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 Dec 21
<i>Products</i>						
Labtech	503	986	1,548	1,991	3,075	3,518
Medtech	1,022	947	2,107	1,421	3,734	3,048
Group items	-3	-1	-5	-2	-8	-5
The Group	1,522	1,932	3,650	3,410	6,801	6,561
<i>Instruments</i>						
Labtech	211	140	367	312	728	673
Medtech	172	84	285	122	509	346
The Group	383	224	652	434	1,237	1,019
<i>Service</i>						
Labtech	72	44	151	91	242	182
Medtech	102	76	205	77	359	231
The Group	174	120	356	168	601	413
Total	2,079	2,276	4,658	4,012	8,639	7,993

Consolidated income statement, condensed

Income statement SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 Dec 21
Net sales	2,079	2,276	4,658	4,012	8,639	7,993
Cost of sales	-1,268	-1,482	-2,846	-2,595	-5,387	-5,136
Gross profit	811	794	1,812	1,417	3,252	2,857
Selling expenses	-522	-438	-1,034	-701	-1,819	-1,486
Administrative expenses	-140	-102	-272	-171	-489	-388
Research and Development	-22	-10	-39	-18	-55	-34
Other operating income and expenses	11	9	9	17	39	47
Operating profit	138	253	476	544	928	996
Financial income and expenses	-44	-16	-93	-20	-142	-69
Profit after financial items	94	237	383	524	786	927
Tax	-18	-59	-82	-120	-168	-206
Profit for the period	76	178	301	404	618	721
<i>Attributable to:</i>						
<i>Equity holders of the Parent Company</i>	74	177	299	403	615	719
<i>Non-controlling interests</i>	2	1	2	1	3	2
Earnings per share (EPS) before dilution, SEK	0.63	1.47	2.47	3.46	5.07	6.03
Earnings per share (EPS) after dilution, SEK	0.62	1.46	2.46	3.44	5.04	6.01
Average number of shares after repurchases, '000s	121,704	121,154	121,753	116,846	121,851	119,418
Number of shares at end of the period, '000	121,740	121,943	121,740	121,943	121,740	121,953
EBITA	240	332	675	658	1,290	1,273
Depreciations included in operating expenses						
- property, plant and equipment	-75	-53	-149	-91	-259	-201
- intangible non-current assets from acquisitions	-93	-71	-182	-101	-331	-250
- other intangible non-current assets	-9	-8	-17	-13	-31	-27

Statement of comprehensive income

SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 Dec 21
Profit for the period	76	178	301	404	618	721
Components that may be reclassified to profit for the period						
Foreign currency translation differences for the period	149	-44	233	7	298	72
Components that can not be reclassified to profit for the period						
Revaluations of defined benefit pension plans	14	6	14	6	8	0
Tax attributable to items not to be reversed in profit or loss	-3	-1	-3	-1	-2	0
Other comprehensive income	160	-39	244	12	304	72
Total comprehensive income	236	139	545	416	922	793
<i>Attributable to:</i>						
<i>Equity holders of the Parent Company</i>	<i>234</i>	<i>139</i>	<i>543</i>	<i>415</i>	<i>918</i>	<i>790</i>
<i>Non-controlling interests</i>	<i>2</i>	<i>0</i>	<i>2</i>	<i>1</i>	<i>4</i>	<i>3</i>

Consolidated balance sheet, condensed

SEKm	30 Jun 22	31 Dec 21	30 Jun 21
Goodwill	5,067	4,528	4,317
Other intangible non-current assets	3,170	2,663	2,518
Property, plant and equipment	886	627	627
Financial non-current assets	149	27	26
Total non-current assets	9,272	7,845	7,488
Inventories	1,565	1,189	1,175
Current receivables	1,505	1,217	1,310
Cash and cash equivalents	351	345	224
Total current assets	3,421	2,751	2,709
Total assets	12,693	10,596	10,197
Total equity	4,541	4,291	3,919
Interest-bearing provisions	197	114	107
Non-interest-bearing provisions	520	489	452
Non-current interest-bearing liabilities	793	788	813
Non-current non-interest-bearing liabilities	10	2	2
Total non-current liabilities	1,520	1,393	1,374
Non-interest-bearing provisions	13	10	12
Current interest-bearing liabilities	4,917	3,314	3,316
Current non-interest-bearing liabilities	1,702	1,588	1,576
Total current liabilities	6,632	4,912	4,904
Total equity and liabilities	12,693	10,596	10,197

Statement of change in Group equity

Statement of change in Group equity, SEKm	1 Jan 22 – 30 Jun 22			1 Jan 21 – 31 Dec 21		
	Equity excl. non-controlling interests	Non-controlling interests	Total equity	Equity excl. non-controlling interests	Non-controlling interests	Total equity
Amount at beginning of period	4,285	6	4,291	1,882	8	1,890
Non-cash issue	-	-	-	1,524	-	1,524
Exercised and issued call options	5	-	5	-9	-	-9
Repurchase of treasury shares	-49	-	-49	-	-	-
Disposal of treasury shares	-	-	-	281	-	281
Dividend	-243	-8	-251	-183	-5	-188
Total comprehensive income	543	2	545	790	3	793
Amount at the end of the period	4,541	0	4,541	4,285	6	4,291

Cash flow statement, condensed

Cash flow statement, condensed SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 Dec 21
Profit after financial items	94	237	383	524	786	927
Adjustment for items not included in cash flow	185	135	400	238	611	449
Income tax paid	-52	-71	-124	-107	-269	-252
Changes in working capital	-21	-101	-121	-271	36	-114
Cash flow from operating activities	206	200	538	384	1,164	1,010
Net investments in non-current assets	-71	-37	-128	-64	-198	-134
Acquisitions and disposals	-295	-2,508	-796	-2,514	-1,125	-2,843
Cash flow from investing activities	-366	-2,545	-924	-2,578	-1,323	-2,977
Dividend paid to shareholders	-243	-183	-243	-183	-243	-183
Exercised and issued call options	5	-	5	-5	1	-9
Förvärv av egna aktier	-	-	-49	-	-49	-
Borrowings	337	2,665	1,319	2,678	1,290	2,649
Repayments on loans	-23	-1	-585	-9	-836	-260
Other financing activities	-51	-266	-88	-288	73	-127
Cash flow from financing activities	25	2,215	359	2,193	236	2,070
Cash flow for the period	-135	-130	-27	-1	77	103
Cash and cash equivalents at beginning of period	475	364	345	216	224	216
Exchange differences on cash and cash equivalents	11	-10	33	9	50	26
Cash and cash equivalents at end of the period	351	224	351	224	351	345

Key financial indicators

	12 months up until				
	30 Jun 22	31 Dec 21	30 Jun 21	31 Dec 20	31 Dec 19
Net sales, SEKm	8,639	7,993	6,984	5,273	3,479
EBITA, SEKm	1,290	1,273	1,173	802	305
EBITA margin, %	14.9%	15.9%	16.8%	15.2%	8.8%
Profit growth, EBITA, %	10%	59%	158%	163%	25%
Return on working capital (P/WC), %	74%	95%	115%	103%	51%
Profit for the period, SEKm	618	721	750	520	142
Return on equity, %	14%	22%	33%	31%	10%
Financial net liabilities, SEKm	5,557	3,870	4,012	700	902
Financial net liabilities/EBITDA, multiple	3.6	2.6	3.0	0.7	2.1
Net debt/equity ratio, multiple	1.2	0.9	1.0	0.4	0.6
Equity ratio, %	36%	40%	38%	46%	45%
Average number of employees	1,943	1,548	1,191	1,004	903
Number of employees at end of the period	2,194	1,802	1,744	1,112	932

Key ratio definitions can be found [here](#).

Key financial indicators per share

	12 months up until				
	30 Jun 22	31 Dec 21	30 Jun 21	31 Dec 20	31 Dec 19
Earnings per share (EPS), SEK	5.07	6.03	6.55	4.63	1.28
Diluted EPS, SEK	5.04	6.01	6.51	4.61	1.28
Cash flow per share from operating activities, SEK	9.55	8.46	9.84	8.47	3.61
Shareholders' equity per share, SEK	37.30	35.14	32.10	16.73	13.07
Average number of shares after repurchases, '000s	121,851	119,418	114,548	112,127	111,083
Average number of shares adjusted for repurchases and dilution, '000s	122,435	119,966	115,305	112,652	111,297
Number of shares outstanding at end of the period, '000s	121,740	121,953	121,943	112,487	112,237
Number of shares outstanding at end of the period after dilution, '000s	122,323	122,501	122,700	113,012	112,451

The number of shares from a historical perspective has been restated to take the share split (1:4) completed in May 2020 into account and has been used in all calculations of metrics for SEK per share. The conversion factor is 4.

Parent company

The Parent Company's net sales for the interim period amounted to SEK 31m (26) and profit after financial items amounted to SEK -125m (8). At the end of the interim period, the Parent Company's net financial debt amounted to SEK 4,605m (3,122). The share capital at the end of the interim period was SEK 62m (62).

Income statement

SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 Dec 21
Net sales	15	12	31	26	56	51
Administrative expenses	-22	-17	-43	-32	-79	-68
Operating profit/loss	-7	-5	-12	-6	-23	-17
Interest income/expenses and similar items	-81	12	-113	14	-128	-1
Profit/loss after financial items	-88	7	-125	8	-151	-18
Appropriations	-	-	-	-	99	99
Profit/loss before taxes	-88	7	-125	8	-52	81
Income tax expense	19	-1	26	-1	12	-15
Profit/loss for the period	-69	6	-99	7	-40	66

Balance sheet

Balance sheet, SEKm	30 Jun 22	31 Dec 21	30 Jun 21
Intangible non-current assets	0	0	0
Tangible non-current assets	0	0	0
Non-current financial assets	7,854	6,978	6,693
Total non-current assets	7,854	6,978	6,693
Current receivables	284	407	184
Total current assets	284	407	184
Total assets	8,138	7,385	6,877
Restricted equity	62	62	62
Unrestricted equity	2,463	2,850	2,795
Total equity	2,525	2,912	2,857
Untaxed reserves	120	120	96
Interest-bearing long-term liabilities	119	235	115
Non-interest-bearing long-term liabilities	1	1	1
Total long-term liabilities	120	236	116
Interest-bearing short-term liabilities	5,341	3,946	3,774
Non-interest-bearing short-term liabilities	32	171	34
Total short-term liabilities	5,373	4,117	3,808
Total equity and liabilities	8,138	7,385	6,877

Fair values on financial instruments

SEKm	30 Jun 22			31 Dec 21		
	Carrying amount	Level 2	Level 3	Carrying amount	Level 2	Level 3
Derivatives measured at fair value through profit or loss	0	0	-	0	0	-
Total financial assets at fair value per level	0	0	-	0	0	-
Derivatives measured at fair value through profit or loss	0	0	-	0	0	-
Contingent considerations	357	-	357	349	-	349
Total financial liabilities at fair value per level	357	0	357	349	0	349

The fair value and carrying amount are recognized in the balance sheet as shown in the table above.

For quoted securities, the fair value is determined on the basis of the asset's quoted price in an active market, level 1. As at the reporting date the Group had no items in this category. For currency contracts and embedded derivatives, the fair value is determined on the basis of observable market data, level 2. For contingent considerations, a cash-flow-based valuation is performed, which is not based on observable market data, level 3. For the Group's other financial assets and liabilities, fair value is estimated to essentially correspond to the carrying amount.

Contingent considerations

SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 dec 21
Carrying amount, opening balance	328	83	349	86	297	86
Acquisitions during the period	16	213	16	213	54	251
Consideration paid	-	-	-31	-6	-31	-6
Revaluation through profit or loss	-	2	4	2	8	6
Reversed through profit or loss	-	-	-	-	-	-
Interest expenses	4	2	6	3	12	9
Exchange differences	9	-3	13	-1	17	3
Carrying amount, closing balance	357	297	357	297	357	349

Pledged assets and contingent liabilities in the Group

SEKm	30 Jun 22	31 Dec 21	30 Jun 21
Contingent liabilities	47	41	41

Reconciliation key ratios

Return on equity	Profit/loss after tax attributable to shareholders, as a percentage of shareholders' proportion of average equity.		
	30 Jun 22	31 Dec 21	30 Jun 21
Profit/loss for the period (roll 12 months)	618	721	750
Average equity	4,277	3,263	2,261
Return on equity	618/4,277=14%	721/3,263=22%	750/2,261=33%

Return on working capital (P/WC)	EBITA in relation to average working capital.		
	30 Jun 22	31 Dec 21	30 Jun 21
EBITA	1,290	1,273	1,173
Average working capital (WC)	1,752	1,347	1,023
P/WC	1,290/1,752=74%	1,273/1,347=95%	1,173/1,023=115%

EBITA	Operating profit before amortization of intangible assets.		
	30 Jun 22	31 Dec 21	30 Jun 21
Operating profit (12 months rolling)	928	996	991
Amortization of intangible assets	362	277	182
EBITA	1,290	1,273	1,173

EBITA margin	EBITA in relation to net sales		
	30 Jun 22	31 Dec 21	30 Jun 21
EBITA	1,290	1,273	1,173
Net sales (12 months rolling)	8,639	7,993	6,984
EBITA margin	1,290/8,639=14.9%	1,273/7,993=15.9%	1,173/6,984=16.8%

Definitions

EBITA	Operating profit before amortization of intangible assets.
EBITDA	Operating profit before depreciation and amortization
Equity per share	Shareholders' proportion of equity divided by the number of shares outstanding at the end of the reporting period
Cash flow per share	Cash flow from operating activities, divided by the average number of shares.
Net debt/equity ratio	Financial net liabilities in relation to shareholders' equity
Earnings per share (EPS)	Shareholders' proportion of profit/loss for the year in relation to the average number of shares outstanding
Profit growth EBITA	This year's EBITA decreased by last year's EBITA divided by last year's EBITA.
Financial net liabilities	Interest-bearing liabilities and interest-bearing provisions, less cash and cash equivalents.
Equity ratio	Equity as a percentage of total assets.
COVID-19 related sales	Big orders of PPE and COVID-19 tests


The key figures presented above are central in order to understand and evaluate AddLife's business and financial position. The key figures are presented in the "Key financial indicators" table and they are commented on in other parts of interim report. For additional information regarding chosen key ratios, please refer to AddLife's annual report 2021. The comparison figures for income and expense items relate to values for the period January–June 2021 and for balance sheet items as at 31 December 2021 if nothing else is stated.

The share

The share capital at the end of the interim period amounted to SEK 62 million (62).

The number of repurchased own shares amounts to 710,689 Class B, corresponding to 0.6 percent of the total number of shares and 0.4 percent of the votes. The average purchase price for shares held in treasury amounts to SEK 99.87 per share. The average number of treasury shares held during the interim period was 697,121 (1,294,850). The share price at June 30, 2022 was SEK 153.60 and the most recent price paid for the AddLife share on July 14, 2022 was SEK 155.60.

SHARE DEVELOPMENT IN ADDLIFE



Turnover and trading	Jan-Jun 2022
Lowest price, SEK	153.60
Highest price, SEK	371.00
Average daily turnover, SEK	79,102,573
Number of traded shares, no	42,192,329
Number of transactions, no	264,039

AddLife has four outstanding call option programmes totalling 2,223,200 Class B shares. Issued call options on repurchased shares have resulted in a calculated dilution effect based on average share price for the interim period of approximately 0.4 percent (0.7). 9,200 share options from the 2019/2023 program have been exercised during the interim period corresponding to 36,800 B-shares.

Outstanding programmes	Number of warrants	Corresponding number of shares	Percentage of total number of shares	Exercise price	Exercise period
2022/2026	150,000	150,000	0.1%	250.07	9 Jun 2025 - 27 Feb 2026
2021/2025	250,000	250,000	0.2%	259.00	10 Jun 2024 - 28 Feb 2025
2020/2024	250,000	1,000,000	0.9%	98.40	19 Jun 2023 - 28 Feb 2024
2019/2023	205,800	823,200	0.7%	76.60	20 Jun 2022 - 28 Feb 2023
Total	855,800	2,223,200			

On 30 June 2022, the number of shareholders amounted to 13,185, where of 96 percent are Swedish owners with respect to capital share. The 10 biggest shareholders controlled 53 percent of number of capital and 63 percent of votes.

Shareholders 2022-06-30	Class A-shares	Class B-shares	Share in %	
			of capital	of votes
Roosgruppen AB	2,165,644	2,824,727	4.08	14.93
Tom Hedelius	2,066,572	23,140	1.71	12.62
SEB Fonder	0	11,671,250	9.53	7.12
State Street Bank & Trust Company	0	8,632,067	7.05	5.26
AMF - Försäkring och Fonder	0	9,146,902	7.47	5.58
Swedbank Fonder	0	7,135,827	5.83	4.35
Verdipapirfond Odin	0	6,580,008	5.37	4.01
AP-fonden	0	5,778,130	4.72	3.53
BNY Mellon NA (Former Mellon)	0	5,001,366	4.13	3.09
Handelsbanken fonder	0	3,902,568	3.19	2.38
Total the 10 biggest shareholders	4,232,216	60,695,985	53.08	62.87
Other shareholders	382,920	56,428,440	46.34	36.70
Total outstanding shares	4,615,136	117,124,425	99.42	99.57
Repurchased own shares Class B	-	710,689	0.58	0.43
Total registered shares	4,615,136	117,835,114	100.00	100.00

Source: Euroclear

Accounting policies

This interim report was prepared in accordance with IFRS and IAS 34 Interim Financial Reporting. Information in accordance with IAS 34.16A exist, except in the financial statements and the related notes also in other parts of the interim report. The interim report for the parent company was prepared in accordance with the Swedish Annual Accounts Act (1995:1554) and the Securities Market Act (2007:528) in compliance with recommendation RFR 2 Accounting for Legal Entities of the Swedish Financial Reporting Board. The accounting policies and basis for calculations applied in the 2021 annual report for AddLife AB were also used in the interim report. The amendments to IFRSs applicable from 1 January, 2022 have no effects to AddLife's financial reports for the interim period ended 30 June, 2022.

Alternative performance measures

AddLife presents certain financial measures in the interim report that are not defined according to IFRS. The Company believes that these measures provide valuable supplemental information to investors and the Company's management as they allow for evaluation of trends and the Company's performance. For additional information regarding chosen key ratios, please refer to AddLife's annual report 2021. Since all companies do not calculate financial measures in the same way these are not always comparable to measures used by other companies. These financial measures should therefore not be considered as a replacement for measurements as defined under IFRS. This report provides information in greater detail regarding definitions of financial performance measures.

Transactions with related parties

No transactions with related parties that materially affected the Group's financial position and earnings took place during the interim period.

Events after the end of the interim period

On July 1, 2022, AddLife acquired all shares in the company JK Lab Nordic AB to the Labtech business area. JK Lab is a specialized distributor of instruments and services in material sampling and has sales of approximately SEK 25m and 6 employees. The Company will be integrated into Bergman Labora.

After the end of the interim period AddLife renegotiated credit facilities corresponding to SEK 2.2 billion with initial maturity second quarter year 2023. The credit facilities mature during the third quarter of 2025 with an extension option of up to a further 24 months.

No other events of significance to the Group occurred after the end of the interim period.

Risks and uncertainties

AddLife's earnings and financial position, as well as its strategic position, are affected by various internal factors within AddLife's control and various external factors over which AddLife has limited influence. AddLife's most significant external risks are the state of the economy and market trends combined with public sector contracts and policy decisions, as well as competition. The risks and uncertainties are the same as in previous periods. For more information, see the section "Risks and uncertainties" in the administration report, in AddLife's annual report 2021. The Parent Company is indirectly affected by the above risks and uncertainties through its function in the Group.

The war in Ukraine has not had a significant economic impact on the financial reports, but it can not be ruled out that this will happen in the future. We follow market developments closely, where we notice rising inflation, higher raw material and shipping costs and greater uncertainty about interest rate developments.

Affirmation

The Board of Directors and the President deem that the interim report gives a true and fair picture of the Company's and the Group's operations, position and earnings, and describes the significant risks and uncertainty factors to which the Company and the Group are exposed.

Stockholm 15 July 2022

Johan Sjö
Chairman of the Board

Birgit Stattin Norinder
Director

Håkan Roos
Director

Eva Nilsagård
Director

Eva Elmstedt
Director

Stefan Hedelius
Director

Kristina Willgård
President and CEO

For further information, contact:
Kristina Willgård, President and CEO: + 46 70 510 12 23
Christina Rubenhag, CFO, +46 70 546 72 22

Conference call

Investors, analysts and the media are invited to a conference call where CEO Kristina Willgård and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10:00 a.m. on July 15th 2022

If you wish to participate via teleconference, [please follow this link](#)>>

Or call in (only sound) +46 8 505 376 58 Conferens-ID: 915 124 356#

The presentation is also available on [AddLife YouTube](#) >>

Financial calendar

- The interim report for 1 January - 30 September 2022 will be published on 27 October 2022
- The Year-end report for 1 January - 31 December 2022 will be published on 2 February 2023

For further information, please contact:

Kristina Willgård, President and CEO, +46 70 510 12 23

Christina Rubenhag, CFO, +46 70 546 72 22

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CET on July 15th, 2022.

AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. info@add.life, www.add.life, org.nr. 556995-8126